FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment
Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...
NASDAQ: AZN
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...
Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer
Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...
Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...
AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions
UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...
Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data
UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...
AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that its MET inhibitor, Orpathys (savolitinib),...
AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study
UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...
Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...
AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that the US Food and Drug...
AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
UK-based pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN) has announced positive results from the PACIFIC-5 III...
AstraZeneca’s Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results
At the 66th American Society of Hematology (ASH) annual meeting, UK pharmaceutical major AstraZeneca (AZ,...
AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...
AstraZeneca Appoints Iskra Reic as EVP, International, Amid Leon Wang’s Investigation in China
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced the appointment of Iskra...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
AstraZeneca’s Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that the Committee for...